Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL9281750 | 0.97 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA | |
| 8-Chlorotheophylline SCHEMBL411139 | 0.80 | POLB (0.57) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA | |
| 8-Chlorotheophylline SCHEMBL5719335 | 0.79 | POLB (0.55) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA | |
| Diphenhydramine SCHEMBL4193326 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA | |
| Diphenylpyraline SCHEMBL1274388 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA | |
| SCHEMBL3181178 | 0.74 | ADORA2A (0.54) | CYP1A2ADORA2BADORA2AADORA1CYP2C19 | |
| SCHEMBL29430494 | 0.72 | ADORA2B (0.49) | ALDH1A1CYP1A2HSD17B10LMNACHRM2 | |
| SCHEMBL11239048 | 0.71 | ATAD2 (0.66) | CYP1A2LMNAADORA2BADORA2AADORA1 | |
| SCHEMBL3175131 | 0.71 | PDE4A (0.57) | CYP1A2ADORA2ACYP2C19 | |
| SCHEMBL18833875 | 0.71 | HPGD (0.55) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459341-B1 | Organic anion lithium ionic cocrystal compounds and compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-10-04 | — | — | US | claimed |
| US-20220226205-A1 | Coated Particles and Their Uses | KENVUE BRANDS LLC | 2022-07-21 | — | — | US | claimed |
| EP-3527192-B9 | AMINO ACID DERIVATIVES AND THEIR USES | JOHNSON & JOHNSON CONSUMER INC (US) | 2022-04-27 | — | — | EP | claimed |
| EP-2986618-B1 | ORGANIC ANION LITHIUM IONIC COCRYSTAL COMPOUNDS AND COMPOSITIONS | UNIV SOUTH FLORIDA (US) | 2021-12-01 | — | — | EP | claimed |
| US-20210284604-A1 | Amino Acid Derivatives and Their Uses | KENVUE BRANDS LLC | 2021-09-16 | — | — | US | claimed |
| EP-3527192-B1 | AMINO ACID DERIVATIVES AND THEIR USES | JOHNSON & JOHNSON CONSUMER INC (US) | 2021-09-08 | — | — | EP | claimed |
| EP-3753562-A1 | COMPOSITIONS COMPRISING THE TROMETHAMINE SALT OF L-AMPICILLIN. | Alpha-1 Biologics LLC (US) | 2020-12-23 | — | — | EP | claimed |
| US-10870665-B1 | Organic anion lithium ionic cocrystal compounds and compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-12-22 | — | — | US | claimed |
| US-20200115331-A1 | Amino Acid Derivatives and Their Uses | KENVUE BRANDS LLC | 2020-04-16 | — | — | US | claimed |
| EP-3634372-A1 | COATED PARTICLES AND THEIR USES | Johnson & Johnson Consumer Inc. (US) | 2020-04-15 | — | — | EP | claimed |
| US-20060241295-A1 | Preparation of pharmaceutical salts of piperazine compounds | SCHERING CORPORATION | 2006-10-26 | — | — | US | claimed |
| WO-2006074269-A2 | PREPARATION OF PHARMACEUTICAL SALTS OF PIPERAZINE COMPOUNDS | SCHERING CORPORATION (US) | 2006-07-13 | — | — | WO | claimed |
| US-6936718-B2 | Preparation of rotamer mixtures of pharmaceutical salts | SCHERING CORPORATION (US) | 2005-08-30 | — | — | US | claimed |
| US-20050171117-A1 | Preparation of pharmaceutical salts | GALA DINESH (US) | 2005-08-04 | — | — | US | claimed |
| EP-1451174-A2 | PROCESS FOR THE PREPARATION OF COMPOSITIONS HAVING AN INCREASED AMOUNT OF PHARMACEUTICALLY ACTIVE SALTS OF ROTAMERS | SCHERING CORPORATION (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1448528-A2 | PREPARATION OF PHARMACEUTICAL SALTS OF 4((Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL)-1'-((2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL)-4'-METHYL-1,4'BIPIPERIDINE AS CCR5-ANTAGONISTS FOR THE TREATMENT OF AIDS AND RELATED HIV INFECTIONS | SCHERING CORPORATION (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003066593-A2 | PREPARATION OF PHARMACEUTICAL SALTS OF 4 ( (Z) - (4-BROMOPHENYL) (ETHOXYIMINO) METHYL )-1'-( (2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL) CARBONYL) -4'-METHYL-1,4' BIPIPERIDINE AS CCR5-ANTAGONISTS FOR THE TREATMENT OF AIDS AND RELATED HIV INFECTIONS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030144510-A1 | receptor which are useful for the treatment of AIDS and related HIV infections, including the compound of Formula I. CCR-5 receptors have also been reported to mediate cell transfer in inflammatory diseases such as arthritis, | SCHERING CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030139446-A1 | Preparation of pharmaceutical salts | SCHERING CORPORATION | 2003-07-24 | — | — | US | claimed |
| WO-2003048153-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS HAVING AN INCREASED AMOUNT OF PHARMACEUTICALLY ACTIVE SALTS OF ROTAMERS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284604-A1 | Amino Acid Derivatives and Their Uses | BCAT2, BCAT1, SLC1A5 | SMN1; SMN2 3546/4885ALDH1A1 809/4885CYP1A2 852/4885 |
| US-20030139446-A1 | Preparation of pharmaceutical salts | PKD1, REN, ADCYAP1R1 | SMN1; SMN2 1486/4885ALDH1A1 1255/4885CYP1A2 871/4885 |
| US-11459341-B1 | Organic anion lithium ionic cocrystal compounds and compositions | SLC10A6, MLX, LPXN | SMN1; SMN2 3280/4885ALDH1A1 1450/4885CYP1A2 870/4885 |
| US-20200115331-A1 | Amino Acid Derivatives and Their Uses | BCAT1, BCAT2, SLC1A5 | SMN1; SMN2 4366/4885ALDH1A1 997/4885CYP1A2 1271/4885 |
| US-20220226205-A1 | Coated Particles and Their Uses | CD63, EPCAM, CD44 | SMN1; SMN2 2837/4885ALDH1A1 4610/4885CYP1A2 4762/4885 |
| US-20060241295-A1 | Preparation of pharmaceutical salts of piperazine compounds | ADCYAP1R1, CYP3A5, RAP2C | SMN1; SMN2 3848/4885ALDH1A1 847/4885CYP1A2 235/4885 |
| US-20030144510-A1 | receptor which are useful for the treatment of AIDS and related HIV infections, including the compound of Formula I. CCR-5 receptors have also been reported to mediate cell transfer in inflammatory diseases such as arthritis, | CCR1, CCR5, CCR6 | SMN1; SMN2 2575/4885ALDH1A1 845/4885CYP1A2 2914/4885 |
| US-10870665-B1 | Organic anion lithium ionic cocrystal compounds and compositions | SLC10A6, MLX, LPXN | SMN1; SMN2 3280/4885ALDH1A1 1450/4885CYP1A2 870/4885 |
| US-20050171117-A1 | Preparation of pharmaceutical salts | PKD1, REN, ADCYAP1R1 | SMN1; SMN2 2045/4885ALDH1A1 1141/4885CYP1A2 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.